Related Experiment Video
Updated: May 12, 2026
Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs
Published on: May 24, 2016
Targeting metastatic melanoma
1Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA. kflaherty@partners.org
Abstract:
Metastatic melanoma has historically been one of the most treatment-refractory types of cancer. Recent headway has been made in understanding the genetic underpinnings of this cancer. A subset of oncogenic events is amenable to targeting with drug therapy. BRAF-targeted therapies represent the first major breakthrough in systemic therapy for melanoma leveraging the new genetic knowledge. Ongoing translational research seeks to identify the most scientifically rational combination treatment strategies to build on single-agent targeted therapy.
Insights
Metastatic melanoma, a difficult-to-treat cancer, is seeing breakthroughs due to understanding its genetics. BRAF-targeted therapies offer a new approach, with research exploring combination treatments for better outcomes.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Metastatic melanoma is historically resistant to treatment.
- Advances in understanding melanoma genetics have identified key oncogenic events.
- Targeting these specific genetic alterations offers new therapeutic avenues.
Purpose of the Study:
- To highlight the significance of genetic understanding in treating metastatic melanoma.
- To introduce BRAF-targeted therapies as a major advancement.
- To emphasize ongoing research in combination treatment strategies.
Main Methods:
- Review of recent genetic discoveries in melanoma.
- Analysis of the impact of BRAF-targeted therapies.
- Discussion of translational research for combination therapies.
Main Results:
- BRAF-targeted therapies represent a significant breakthrough in systemic melanoma treatment.
- Genetic knowledge is crucial for developing effective targeted therapies.
- Combination strategies are being investigated to enhance treatment efficacy.
Conclusions:
- Targeted therapies based on genetic insights have revolutionized melanoma treatment.
- Further research into combination therapies holds promise for improving outcomes in metastatic melanoma.
- Understanding the genetic landscape is key to overcoming treatment resistance.
